BIOMAT Database Logo BIOMAT Database Logo

PDE4 inhibitors: new xanthine analogues. 1998

J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Chiroscience Ltd, Cambridge Science Park, UK. johnmontana@chiroscience.com

Novel xanthine analogues are described which are selective PDE4 inhibitors with improved therapeutic potential over theophylline.

UI MeSH Term Description Entries
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D005289 Ferrets Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE. Domestic Polecat,Domestic Polecats,European Polecat,European Polecats,Ferret,Mustela putorius,Mustela putorius furo,Polecat, Domestic,Polecat, European,Polecats, Domestic,Polecats, European
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012871 Skin Diseases Diseases involving the DERMIS or EPIDERMIS. Dermatoses,Skin and Subcutaneous Tissue Disorders,Dermatosis,Skin Disease
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo
D014839 Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Emesis
D014970 Xanthines Purine bases found in body tissues and fluids and in some plants.
D015105 3',5'-Cyclic-AMP Phosphodiesterases Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP. 3',5'-Cyclic AMP 5'-Nucleotidohydrolase,3',5'-Cyclic-Nucleotide Phosphodiesterase,CAMP Phosphodiesterase,3',5' Cyclic AMP Phosphodiesterase,3',5'-Cyclic AMP Phosphodiesterase,3',5'-Cyclic Nucleotide Phosphodiesterase,3',5'-Cyclic-AMP Phosphodiesterase,3',5'-Nucleotide Phosphodiesterase,3,5-Cyclic AMP 5-Nucleotidohydrolase,3,5-Cyclic AMP Phosphodiesterase,3',5' Cyclic AMP 5' Nucleotidohydrolase,3',5' Cyclic AMP Phosphodiesterases,3',5' Cyclic Nucleotide Phosphodiesterase,3',5' Nucleotide Phosphodiesterase,3,5 Cyclic AMP 5 Nucleotidohydrolase,3,5 Cyclic AMP Phosphodiesterase,5'-Nucleotidohydrolase, 3',5'-Cyclic AMP,5-Nucleotidohydrolase, 3,5-Cyclic AMP,AMP 5'-Nucleotidohydrolase, 3',5'-Cyclic,AMP 5-Nucleotidohydrolase, 3,5-Cyclic,AMP Phosphodiesterase, 3',5'-Cyclic,AMP Phosphodiesterase, 3,5-Cyclic,Nucleotide Phosphodiesterase, 3',5'-Cyclic,Phosphodiesterase, 3',5'-Cyclic AMP,Phosphodiesterase, 3',5'-Cyclic Nucleotide,Phosphodiesterase, 3',5'-Cyclic-AMP,Phosphodiesterase, 3',5'-Cyclic-Nucleotide,Phosphodiesterase, 3',5'-Nucleotide,Phosphodiesterase, 3,5-Cyclic AMP,Phosphodiesterase, CAMP,Phosphodiesterases, 3',5'-Cyclic-AMP

Related Publications

J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Kinetin & Kinetin Analogues as Substrates & Inhibitors of Xanthine Oxidase.
July 1962, Plant physiology,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
New orally active PDE4 inhibitors with therapeutic potential.
August 2004, Bioorganic & medicinal chemistry,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
September 2004, Chemical & pharmaceutical bulletin,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
New orally active PDE4 inhibitors with therapeutic potential.
January 2004, Bioorganic & medicinal chemistry letters,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Molecular Docking Studies on Isocytosine Analogues as Xanthine Oxidase Inhibitors.
July 2018, Drug research,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Benzofuran based PDE4 inhibitors.
June 1999, Bioorganic & medicinal chemistry,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
PDE4 inhibitors: current status.
October 2008, British journal of pharmacology,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Benz-fused mesoionic xanthine analogues as inhibitors of cyclic-AMP phosphodiesterase.
June 1981, Journal of medicinal chemistry,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
Design and synthesis of xanthine analogues as potent and selective PDE5 inhibitors.
November 2002, Bioorganic & medicinal chemistry letters,
J G Montana, and N Cooper, and H J Dyke, and L Gowers, and J P Gregory, and P G Hellewell, and J Miotla, and K Morris, and R Naylor, and B Tuladhar, and J B Warneck
A preliminary investigation of mesoionic xanthine analogues as inhibitors of platelet aggregation.
August 2000, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!